PolyPid stock: PolyPid presents 2,185-patient infection analysis for PolyPid stock

Published on 10/22/2026 at 05:29 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

PolyPid presents pooled data from 2,185 patients, showing 16 percent versus 27 percent heavy growth. PolyPid stock has a November 28 FDA date.

Clinical evidence and regulatory dates

On October 21, 2026, PolyPid announced a pooled analysis of 2,185 patients.
Heavy bacterial growth occurred in 16 percent versus 27 percent with standard care.
The FDA PDUFA goal date is November 28, 2026.

PYPD, IL0011326795, Illustration mit AI erstellt.

PolyPid (IL0011326795) is presenting pooled microbiology data from 2,185 patients at IDWeek on October 22, 2026. The company announced the analysis on October 21, 2026, according to GlobeNewswire. For PolyPid stock, the study adds clinical detail ahead of the companys regulatory milestones.

Microbiology adds a sharper measure

The analysis pools SHIELD I, SHIELD II and a phase 2 trial. In the culture-positive infection subset, heavy bacterial growth occurred in 16 percent of patients receiving D-PLEX100 plus standard care, versus 27 percent with standard care alone, according to GlobeNewswire. Breakthrough infections occurred after a median of 10.0 days with D-PLEX100, compared with 6.5 days for standard care.

The release describes the findings as exploratory and says the culture-positive subset included 134 patients. That distinction matters because the analysis adds microbiology context to the earlier Phase 3 result rather than replacing the primary efficacy evidence.

Three dated milestones carry figures

On September 14, 2026, PolyPid submitted the European marketing application for D-PLEX100. On October 1, 2026, the European Medicines Agency validated that application, while the supporting Phase 3 program showed a 60 percent relative reduction in surgical-site infections, according to PolyPid. The October 21, 2026 announcement of the 2,185-patient microbiology presentation is the latest milestone.

What dates matter next?

PolyPid has scheduled a virtual Investor Day for October 28, 2026, at 11:30 a.m. ET, where management plans to discuss its PolyPid 2030 strategy and D-PLEX100, according to PolyPid. The FDA has set November 28, 2026, as the PDUFA goal date for the D-PLEX100 application.

Regulatory timing stays central

PolyPid develops long-acting, controlled-release medicines, with D-PLEX100 designed to deliver doxycycline locally for 30 days after surgery. The latest Nasdaq quote was USD 5.07 on October 21, 2026, at 4:00 p.m. ET, while the companys market capitalization stood at USD 103.0 million.